Composition for treating or preventing glomerulopathy

Details Composition for treating or preventing glomerulopathy Composition for treating or preventing glomerulopathy

2005-04-12

2005-04-12

Shameem, Golam M M (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S469000, C548S495000, C549S059000, C514S444000

Reexamination Certificate

active

06878739

ABSTRACT:
A composition for treating or preventing glomerulopathy which contains a compound of the formula (I):wherein, for example,R1and R2are each independently hydrogen atom, optionally substituted lower alkyl, optionally substituted aralkyl, etc.;R3is 1,4-phenylene and 2,5-thiophendiyl;R4is the substituents represented by the formula, etc.:whereinR5is hydrogen atom, optionally substituted amino, etc.; andY is NHOH or OH, its optically active substance, their pharmaceutically acceptable salt, or hydrate thereof.

REFERENCES:
patent: 6150394 (2000-11-01), Watanabe et al.
patent: 6207698 (2001-03-01), Wantanabe et al.
patent: 6423729 (2002-07-01), Kurihara et al.
patent: 6441021 (2002-08-01), Wantanabe et al.
patent: 0 757 037 (1997-02-01), None
patent: 0 757 984 (1997-02-01), None
patent: 0 765 661 (1997-04-01), None
patent: 0 915 086 (1999-05-01), None
patent: 915086 (1999-05-01), None
patent: 0 950 656 (1999-10-01), None
patent: 7 300426 (1995-11-01), None
patent: 9 87178 (1997-03-01), None
patent: 9 110864 (1997-04-01), None
patent: 9535276 (1995-12-01), None
patent: 9600214 (1996-01-01), None
patent: 9705865 (1997-02-01), None
patent: 9727174 (1997-07-01), None
patent: 9744315 (1997-11-01), None
patent: WO 9745402 (1997-12-01), None
patent: 9745402 (1997-12-01), None
patent: 9803166 (1998-01-01), None
patent: 9843963 (1998-10-01), None
J.J.N., vol. 36, p. 106 (1994).
J.J.N., vol. 39, p. 220 (1997).
J.J.N., vol. 39, p. 300 (1997).
C.G. Knight et al., FEBS, vol. 296, No. 3, “A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinase,” pp. 263-266 (1992).
Y. Okada et al., Eur. J. Biochem., vol. 194, Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts (Purification and activation of the precursor and enzymic properties), pp. 721-730 (1990).
Y. Okada et al., J. Bio. Chem., vol. 267, No. 30, “Matrix Metalloproteinase 9 (92-kDA Gelatinase/Type IV Collagenase) from HT 1080 Human Fibrosarcoma Cells,” pp. 21712-21719 (1992).
Yoshinori Tamura et al., J. Med. Chem., vol. 41, No. 4, “Highly Selective and Orally Active Inhibitors of type IV Collagenase (MMP-9 and MMP-2); N-Sulfonylamino Acid Derivatives,” pp. 640-649 (1998).
R.V. Ward et al., J. Biochem,. vol. 278, “The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex,” pp. 179-187 (1991).
Albert Wolthuis et al., Am. J. Pathol., vol. 143, No. 4, “Cell Density Modulates Growth, Extracellular Matrix, and Protein Synthesis of Cultured Rat Mesangial Cells,” pp. 1209-1219 (1993).
Marti et al., “Molecular Characterization of a Low-Molecular-Mass Matrix Metalloproteinase Secreted by Glomerular Mesangial Cells as Pump-1”,Biochemical Journal(1992), vol. 285, pp. 899-905, Portland Press, London, GB, vol. 285, XP002913114, ISSN: 0264-6021.

Affiliated with

Also associated with

Rating

Composition for treating or preventing glomerulopathy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition for treating or preventing glomerulopathy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for treating or preventing glomerulopathy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3403069